Compounds > 1,1,1,2,2-pentafluoro-7-phenylheptan-3-one
Page last updated: 2024-11-13

1,1,1,2,2-pentafluoro-7-phenylheptan-3-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,1,1,2,2-pentafluoro-7-phenylheptan-3-one: an iPLA2 GVIA inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24995215
CHEMBL ID460312
CHEBI ID188183
SCHEMBL ID3489580
MeSH IDM0527826

Synonyms (20)

Synonym
fkgk11
CHEMBL460312
1,1,1,2,2-pentaluoro-7-phenylheptan-3-one
CHEBI:188183
fkgk 11
1071000-98-0
1,1,1,2,2-pentafluoro-7-phenyl-3-heptanone
SCHEMBL3489580
HMS3648G06
J-001702
DTXSID50648375
1,1,1,2,2-pentafluoro-7-phenylheptan-3-one
HY-116018
sr-01000946364
SR-01000946364-1
1,1,1,2,2-pentafluoro-7-phenyl-heptan-3-one
fkgk-11
WSB00098
CS-0063534
AKOS040748357
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID480970Inhibition of human group 5 sPLA2 at 0.091 mol fraction after 30 mins2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2.
AID1301354Inhibition of secretory phospholipase A2 in rat renal mesangial cells assessed as suppression of IL-1beta/forskolin stimulated PGE2 formation preincubated for 20 mins prior to IL-1beta/forskolin challenge at 10 uM measured after 24 hrs by PGE2-specific EL2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Inhibitors of secreted phospholipase A2 suppress the release of PGE2 in renal mesangial cells.
AID414228Inhibition of human group 4A cPLA2 at 0.091 mol fraction by mixed micelle-based assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.
AID480973Inhibition of human recombinant group 6A iPLA2 expressed in Sf9 insect cells after 30 mins by Dole assay2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2.
AID414230Inhibition of human group 5 sPLA2 at 0.091 mol fraction by mixed micelle-based assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.
AID1602893Inhibition of human recombinant G6A iPLA2 at 0.091 mole fraction using arachidonyl-1-14C PAPC and PAPC incubated for 30 mins by HPLC-MS analysis based radioactivity-based group specific mixed micelle assay relative to control2019Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
β-Lactones: A Novel Class of Ca
AID480969Inhibition of human group 5A cPLA2 at 0.091 mol fraction after 30 mins by Dole assay2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2.
AID1602895Inhibition of human recombinant G4A cPLA2 at 0.091 mole fraction using arachidonyl-1-14C PAPC PAPC and PIP2 incubated for 30 mins by HPLC-MS analysis based radioactivity-based group specific mixed micelle assay2019Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
β-Lactones: A Novel Class of Ca
AID1602894Inhibition of human recombinant G6A iPLA2 using arachidonyl-1-14C PAPC and PAPC incubated for 30 mins by HPLC-MS analysis based radioactivity-based group specific mixed micelle assay2019Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
β-Lactones: A Novel Class of Ca
AID414232Inhibition of human group 6A iPLA2 by mixed micelle-based assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.
AID480968Inhibition of human recombinant group 6A iPLA2 expressed in Sf9 insect cells at 0.091 mol fraction after 30 mins by Dole assay2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2.
AID1602897Inhibition of human recombinant G5 sPLA2 at 0.091 mole fraction using arachidonyl-1-14C PAPC and PAPC by HPLC-MS analysis based radioactivity-based group specific mixed micelle assay relative to control2019Journal of medicinal chemistry, 03-28, Volume: 62, Issue:6
β-Lactones: A Novel Class of Ca
AID414229Inhibition of human group 6A iPLA2 at 0.091 mol fraction by mixed micelle-based assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (33.33)29.6817
2010's5 (55.56)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.29 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pacocf3
[no description available]		2.0410alpha-haloketone
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.0610taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		2.0710divalent inorganic anion;
phosphite ion
deamino arginine vasopressin
Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.		2.0710heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
lysophosphatidylcholines
lysophosphatidylcholine : An acylglycerophosphocholine resulting from partial hydrolysis of a phosphatidylcholine, which removes one of the fatty acyl groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl.		2.6101-O-acyl-sn-glycero-3-phosphocholine
6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one
6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one: structure given in first source; potent irreversible, mechanism-based inhibitor of myocardial calcium-independent phospholipase A2		2.4720naphthalenes
pituitrin
Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).		2.0710
1,1,1-trifluoro-6-(naphthalen-2-yl)hexan-2-one
1,1,1-trifluoro-6-(naphthalen-2-yl)hexan-2-one: inhibits Group VIA Ca(II)-independent phospholipase A2; structure in first source		2.5120
ConditionIndicatedRelationship StrengthStudiesTrials
Wallerian Degeneration
Degeneration of distal aspects of a nerve axon following injury to the cell body or proximal portion of the axon. The process is characterized by fragmentation of the axon and its MYELIN SHEATH.		02.0410
Disease Exacerbation
[description not available]		02.0510
Allergic Encephalomyelitis
[description not available]		02.0510
MS (Multiple Sclerosis)
[description not available]		02.0510
Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)		02.0510
Cancer of Ovary
[description not available]		02.0610
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.0610